A leading gene therapy company has initiated a Phase I/II trial of ProSavin, a novel gene-based treatment for Parkinson's disease.
Oxford BioMedica is beginning patient recruitment for the trial which will be held at the Henri Mondor Hospital in Creteil, France.
The trial will aim to assess the safety and efficacy of ProSavin.
ProSavin uses gene therapy to restore dopamine production in the brain, relieving the degeneration of dopamine-producing nerve cells which causes Parkinson's.
Professor Alan Kingsman, chief executive of Oxford BioMedica, said: "The strength of the preclinical safety and efficacy data with ProSavin has established strong scientific support for the clinical development of this pioneering product candidate for Parkinson's disease."
Dr Stephane Palfi, a neurosurgeon at the Henri Mondor Hospital, added that the current standard therapy for Parkinson's is only partially effective in the mid to late stages of the disease.
She continued to say that ProSavin could potentially address this unmet medical need by offering a lasting benefit to people with Parkinson's.
According to the Parkinson's Disease Society, approximately 120,000 individuals in the UK have Parkinson's.
Please click here, for advice about finding the right type of care.